Strategies for implementing long‐acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study
Journal of the International AIDS Society · 2025
DOI: 10.1002/jia2.26497 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the International AIDS Society, 2025. Verfasst von Katherine L Nelson und 20 weiteren Autor:innen. Beteiligte Einrichtung: ViiV Healthcare, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Health Personnel, Black or African American. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare.
Abstract (Originalsprache)
Introduction
Long‐acting cabotegravir (CAB LA) is the first LA agent approved for HIV pre‐exposure prophylaxis. EBONI (NCT05514509) is a Phase 4 implementation study evaluating the implementation of CAB LA delivery to Black cis‐ and transgender (cis‐and‐trans) women in clinics located in the United States, including infectious disease (ID), primary care (PC) and women's health (WH) clinics. We present interim perspectives, considerations and strategies from healthcare professionals’ (HCPs’) experiences during the initial implementation stages of administering CAB LA.
Methods
From August 2022 to June 2024, through quantitative surveys (prior to implementation [baseline] and Month 4 [M4]) and/or structured qualitative interviews (M4), HCPs provided their perceptions and experiences of integrating CAB LA in their clinical settings that served Black cis‐and‐trans women. Monthly implementation monitoring (IM) calls were also conducted. Survey data were analysed using descriptive statistics. Qualitative and IM data were coded and analysed using a Framework Analysis approach grounded in the Consolidated Framework for Implementation Research.
Results
Ninety‐two HCPs across 20 sites completed baseline and M4 surveys; 57% were cisgender female and 43% were Black. HCPs across clinic types developed innovative approaches to support CAB LA implementation, with few HCPs (< 10%) reporting concerns about practice preparation. Initial HCP considerations related to patient adherence, insurance verification and patient identification reduced by M4 (absolute % reduction: 5–14%; 5–9%; and 4–12%, respectively). HCPs across clinic types serving Black women reported successful implementation strategies, including addressing medical mistrust and patient miseducation, staff training and reminder or tracking systems. Useful implementation strategies unique to clinic types included using electronic medical records to document whether patients were offered CAB LA (PC), designating specific days for administering injections (WH) and creating time for discussion with patients (ID).
Conclusions
A range of strategies across clinics that routinely serve Black cis‐and‐trans women were used to support CAB LA implementation. Implementing CAB LA in clinical settings can be bolstered by addressing population‐specific concerns, increasing staff/patient education about CAB LA and modifying clinical flows. Lessons learned in EBONI can help support future integration for Black cis‐ and transgender women and provide valuable insights for various clinical environments. ClinicalTrials.gov number NCT05514509
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ViiV Healthcare, Durham, North Carolina, USA.
- MadeWell OBGYN, Dallas, Texas, USA.
- Emory University School of Medicine, Atlanta, Georgia, USA.
- Legacy Community Health Services, Houston, Texas, USA.
- Whitman-Walker Institute, Washington, DC, USA.
- Washington Health Institute, Washington, DC, USA.
ORCID-Profile: Courtney Peasant Bonner, Sara M Andrews, Nanlesta Pilgrim
Förderung
- ViiV Healthcare
Zitieren
APA
Nelson, K. L., Evans Cooper, T., Lawson, Y., Baker, D., Mocherla, S., Dieterich, M., Hodge, T., Dyson, A., Sutherland-Philips, D., Swygard, H., Petty, L., Jeffery, P., Sutton, K., Bonner, C. P., Andrews, S. M., Chang, S., Budnik, P., Smith, K., de Ruiter, A., …, & Pilgrim, N. (2025). Strategies for implementing long‐acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26497
Vancouver
Nelson KL, Evans Cooper T, Lawson Y, Baker D, Mocherla S, Dieterich M, et al. Strategies for implementing long‐acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study. Journal of the International AIDS Society. 2025. doi:10.1002/jia2.26497
BibTeX
@article{Nelson2025,
author = {Nelson, Katherine L and Evans Cooper, Tammeka and Lawson, Yolanda and Baker, Dylan and Mocherla, Satish and Dieterich, Megan and Hodge, Theo and Dyson, Alftan and Sutherland-Philips, Denise and Swygard, Heidi and Petty, Lisa and Jeffery, Peter and Sutton, Kenneth and Bonner, Courtney Peasant and Andrews, Sara M and Chang, Samantha and Budnik, Piotr and Smith, Kimberly and de Ruiter, Annemiek and Czarnogorski, Maggie and Pilgrim, Nanlesta},
title = {Strategies for implementing long‐acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study},
journal = {Journal of the International AIDS Society},
year = {2025},
doi = {10.1002/jia2.26497}
}
EUVIMED